The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) which commenced in 1990 made it possible to use common scientific and technical methods in drug development in Japan, the United States and EU. As a result, in approval reviews of medicinal drugs in Japan, results from foreign clinical trials are utilised based on bridging development strategy as stipulated by ICH Guideline E5.